Cargando…

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation accounts for a large proportion of AML patients and diagnosed with poor prognosis. Although the prognosis of FLT3-ITD AML has been greatly improved, the drug resistance frequently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Xinhua, Wang, Peihong, Zhang, Weina, Wang, Jiayi, Cai, Mansi, Jiang, Hua, Wu, Yingli, Shan, Huizhuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691066/ https://www.ncbi.nlm.nih.gov/pubmed/38037057 http://dx.doi.org/10.1186/s12935-023-03142-y

Ejemplares similares

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
por: Wang, Peihong, et al.
Publicado: (2021)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Overcoming AC220 resistance of FLT3-ITD by SAR302503
por: Kesarwani, M, et al.
Publicado: (2013)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
por: Zhang, Yvyin, et al.
Publicado: (2023)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
por: Reiter, K, et al.
Publicado: (2018)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia
por: Peschel, Ines, et al.
Publicado: (2017)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
por: He, Bai‐Liang, et al.
Publicado: (2020)

Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
por: Wobus, Manja, et al.
Publicado: (2015)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
por: Heydt, Q, et al.
Publicado: (2018)

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia
por: Ueno, Yoko, et al.
Publicado: (2019)

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
por: Lopez‐Reyes, Rosa G., et al.
Publicado: (2020)

Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
por: Spohr, Corinna, et al.
Publicado: (2021)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
por: Karnan, Sivasundaram, et al.
Publicado: (2021)

Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD(+) Acute Myeloid Leukemia
por: Bregante, Javier, et al.
Publicado: (2021)

NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia
por: Chen, Yongfeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ptpnshdtksqnn0lcj9o59i4ius